Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAvPAL-PEG Dose-Finding Study in PKU
NCT00925054Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Sep 2009
- Primary completion
- Jun 2015
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegvaliase in phenylketonuria (PKU) (5 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: Blood Phenylalanine Concentrations at Week 16. Started Sep 2009; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT00925054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00925054.